Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.72 AUD | -1.05% | -6.35% | -23.25% |
03/06 | Swissmedic Grants Mayne Pharma Group Expanded Kapanol Dosage Approvals in Switzerland | MT |
24/05 | Mayne Pharma Reiterates H2 FY24 Outlook in Wake of Change Healthcare Cyberattack | MT |
Sales 2024 * | 38Cr 25Cr 2.1TCr | Sales 2025 * | 43Cr 28Cr 2.34TCr | Capitalization | 38Cr 25Cr 2.11TCr |
---|---|---|---|---|---|
Net income 2024 * | -8.8Cr -5.79Cr -483.65Cr | Net income 2025 * | -1.9Cr -1.25Cr -104.42Cr | EV / Sales 2024 * | 0.79 x |
Net cash position 2024 * | 7.99Cr 5.26Cr 439.09Cr | Net cash position 2025 * | 5.31Cr 3.49Cr 291.57Cr | EV / Sales 2025 * | 0.78 x |
P/E ratio 2024 * |
-4.36
x | P/E ratio 2025 * |
-19.4
x | Employees | 967 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.67% |
Latest transcript on Mayne Pharma Group Limited
1 day | -1.05% | ||
1 week | -6.35% | ||
Current month | -6.35% | ||
1 month | -35.08% | ||
3 months | -32.57% | ||
6 months | -20.00% | ||
Current year | -23.25% |
Managers | Title | Age | Since |
---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 01/22/01 |
Aaron Gray
DFI | Director of Finance/CFO | - | 29/22/29 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 30/18/30 |
Patrick Blake
BRD | Director/Board Member | 59 | 28/18/28 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 01/22/01 |
Date | Price | Change | Volume |
---|---|---|---|
07/24/07 | 4.72 | -1.05% | 400,666 |
06/24/06 | 4.77 | -3.25% | 380,869 |
05/24/05 | 4.93 | +0.61% | 156,941 |
04/24/04 | 4.9 | -2.20% | 213,285 |
03/24/03 | 5.01 | -0.60% | 168,919 |
Delayed Quote Australian S.E., June 07, 2024 at 11:41 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.25% | 25Cr | |
+19.64% | 4.33TCr | |
+21.25% | 2.22TCr | |
+18.92% | 1.54TCr | |
+53.19% | 1.27TCr | |
-0.05% | 678.76Cr | |
-11.11% | 670.81Cr | |
-8.87% | 572.55Cr | |
+14.68% | 549.79Cr | |
+6.91% | 478.4Cr |
- Stock Market
- Equities
- MYX Stock